154 related articles for article (PubMed ID: 37862114)
21. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer sheds the αvβ3 integrin in vivo through exosomes.
Krishn SR; Singh A; Bowler N; Duffy AN; Friedman A; Fedele C; Kurtoglu S; Tripathi SK; Wang K; Hawkins A; Sayeed A; Goswami CP; Thakur ML; Iozzo RV; Peiper SC; Kelly WK; Languino LR
Matrix Biol; 2019 Apr; 77():41-57. PubMed ID: 30098419
[TBL] [Abstract][Full Text] [Related]
23. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
Liu B; Li X; Li J; Jin H; Jia H; Ge X
Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
[TBL] [Abstract][Full Text] [Related]
24. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
25. The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer.
Liu C; Gao Y; Ni J; Chen S; Hu Q; Wang C; Hu M; Chen M
BMC Cancer; 2022 Jul; 22(1):788. PubMed ID: 35850679
[TBL] [Abstract][Full Text] [Related]
26. Necroptosis-Related Prognostic Model for Pancreatic Carcinoma Reveals Its Invasion and Metastasis Potential through Hybrid EMT and Immune Escape.
Liu H; Li Z; Zhang L; Zhang M; Liu S; Wang J; Yang C; Peng Q; Du C; Jiang N
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371833
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of fatty acid metabolism-related gene signatures for predicting prognosis in patients with prostate cancer.
Wang H; Liu Z; Wang Y; Han D; Du Y; Zhang B; He Y; Liu J; Xiong W; Zhang X; Gao Y; Shang P
PeerJ; 2023; 11():e14646. PubMed ID: 36643625
[TBL] [Abstract][Full Text] [Related]
28. The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3K signaling.
Lamb LE; Zarif JC; Miranti CK
Cancer Res; 2011 Apr; 71(7):2739-49. PubMed ID: 21310825
[TBL] [Abstract][Full Text] [Related]
29. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
30. [Establishment of a prostate cancer prognostic risk model based on the TCGA database and inflammation-related genes].
Zhong RF; Wu JC; Ling JC; Meng JL; Fan S
Zhonghua Nan Ke Xue; 2022 Nov; 28(11):985-995. PubMed ID: 37846114
[TBL] [Abstract][Full Text] [Related]
31. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.
Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
Front Immunol; 2022; 13():914577. PubMed ID: 35757739
[TBL] [Abstract][Full Text] [Related]
33. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
34. Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram.
Rui X; Shao S; Wang L; Leng J
BMC Cancer; 2019 Dec; 19(1):1179. PubMed ID: 31795990
[TBL] [Abstract][Full Text] [Related]
35. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
36. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
37. Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer.
Ren C; Wang Q; Wang S; Zhou H; Xu M; Li H; Li Y; Chen X; Liu X
Front Endocrinol (Lausanne); 2023; 14():1148117. PubMed ID: 37033267
[TBL] [Abstract][Full Text] [Related]
38. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer.
Hu D; Cao Q; Tong M; Ji C; Li Z; Huang W; Jin Y; Tong G; Wang Y; Li P; Zhang H
BMC Med Genomics; 2022 Feb; 15(1):24. PubMed ID: 35135561
[TBL] [Abstract][Full Text] [Related]
39. Effects of immune inflammation in head and neck squamous cell carcinoma: Tumor microenvironment, drug resistance, and clinical outcomes.
Zhu L; Wang Y; Yuan X; Ma Y; Zhang T; Zhou F; Yu G
Front Genet; 2022; 13():1085700. PubMed ID: 36579330
[No Abstract] [Full Text] [Related]
40. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer.
Liu Y; Wang CL; Pang ZQ; Gao K; Shen LK; Xu WH; Ren MH
J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
